These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 26943962)
1. Immunomodulation by vitamin D in multiple sclerosis: More than IL-17. Smolders J; Muris AH; Damoiseaux J J Neuroimmunol; 2016 Mar; 292():79-80. PubMed ID: 26943962 [No Abstract] [Full Text] [Related]
2. Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Toghianifar N; Ashtari F; Zarkesh-Esfahani SH; Mansourian M J Neuroimmunol; 2015 Aug; 285():125-8. PubMed ID: 26198928 [TBL] [Abstract][Full Text] [Related]
3. The elusive biomarker for personalized medicine in multiple sclerosis: the search continues. Rudick RA Neurology; 2012 Aug; 79(6):498-9. PubMed ID: 22573625 [No Abstract] [Full Text] [Related]
14. Vitamin D in MS: a vitamin for 4 seasons. Ascherio A; Marrie RA Neurology; 2012 Jul; 79(3):208-10. PubMed ID: 22700805 [No Abstract] [Full Text] [Related]
15. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels. Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963 [TBL] [Abstract][Full Text] [Related]
16. Unfavorable outcomes during treatment of multiple sclerosis with high doses of vitamin D. Fragoso YD; Adoni T; Damasceno A; de Albuquerque Damasceno CA; Ferreira ML; Finkelzstejn A; Gomes S; Goncalves MV; Grzesiuk AK; Lins S; Mendes MF; de Oliveira FT; Parolin MF; Rocha CF; Tauil CB J Neurol Sci; 2014 Nov; 346(1-2):341-2. PubMed ID: 25183235 [No Abstract] [Full Text] [Related]
17. Effect of high-dose vitamin D Røsjø E; Lossius A; Abdelmagid N; Lindstrøm JC; Kampman MT; Jørgensen L; Sundström P; Olsson T; Steffensen LH; Torkildsen Ø; Holmøy T Mult Scler; 2017 Mar; 23(3):395-402. PubMed ID: 27325604 [TBL] [Abstract][Full Text] [Related]
18. Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study. Simpson S; Stewart N; van der Mei I; Otahal P; Charlesworth J; Ponsonby AL; Blizzard L; Dwyer T; Pittas F; Gies P; Taylor B J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):200-7. PubMed ID: 24790215 [TBL] [Abstract][Full Text] [Related]
19. Interleukin-17A Levels Vary in Relapsing-Remitting Multiple Sclerosis Patients in Association with Their Age, Treatment and the Time of Evolution of the Disease. Guerrero-García Jde J; Castañeda-Moreno VA; Torres-Carrillo N; Muñoz-Valle JF; Bitzer-Quintero OK; Ponce-Regalado MD; Mireles-Ramírez MA; Valle Y; Ortuño-Sahagún D Neuroimmunomodulation; 2016; 23(1):8-17. PubMed ID: 26599431 [TBL] [Abstract][Full Text] [Related]
20. Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. Røsjø E; Myhr KM; Løken-Amsrud KI; Bakke SJ; Beiske AG; Bjerve KS; Hovdal H; Lilleås F; Midgard R; Pedersen T; Šaltytė Benth J; Torkildsen Ø; Wergeland S; Michelsen AE; Aukrust P; Ueland T; Holmøy T J Neuroimmunol; 2015 Mar; 280():21-8. PubMed ID: 25773151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]